Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
CVRx, Inc. (CVRX)
USD5.21
+0.05 (+0.97%)
US NASDAQ Healthcare Medical - Devices
Address
9201 West Broadway Avenue 55445
Minneapolis, MN, US
Minneapolis, MN, US
CEO
Kevin Hykes
Website
cvrx.com
IPO
2021-06-30
CIK 1235912 ISIN US1266381052
Description
CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD5.21
+0.05 (+0.97%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
324.7K
Beta
0.77
Float Shares
18.20M
Free Float %
69.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -23.84% | -27.01% | -32.52% | +6.46% | -40.85% | -25.77% | -3.13% | -57.12% | -81.18% | -81.18% | -81.18% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (7 ratings, all time)
Buy
Price Targets & DCF
Current price
5.21
Low
10.00
+91.9%
Consensus
10.00
+91.9%
Median
10.00
+91.9%
High
10.00
+91.9%
Ratings Trend (MoM)
86% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 5 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
10.00
+91.9%
|
| Last Year | 2 |
11.50
+120.7%
|
| All Time | 9 |
14.89
+185.8%
|
Quality scores
Altman Z-Score
-6.87
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%+10.5% Q1'26: +19.6% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+23.0% Q1'26: +5.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-92.0% Q1'26: -83.2% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-83.8% Q1'26: -82.3% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%-329.7% Q1'26: -307.1% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+15.4% Q1'26: +1.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-1.09× Q1'26: -1.21× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 6 EPS Ana. |
Dec 2027 5 Rev. Ana. 5 EPS Ana. |
Dec 2028 4 Rev. Ana. 4 EPS Ana. |
Dec 2029 3 Rev. Ana. 2 EPS Ana. |
Dec 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
13.04M
est: 13.25M (-1.6%)
|
22.47M
est: 22.21M (+1.2%)
|
39.30M
est: 44.39M (-11.5%)
|
51.29M
est: 51.01M (+0.6%)
|
56.65M
est: 56.39M (+0.5%)
|
65.20M
64.97M – 65.57M
+15.6% YoY
|
76.06M
75.04M – 77.14M
+16.7% YoY
|
95.46M
95.35M – 95.57M
+25.5% YoY
|
120.20M
117.75M – 123.48M
+25.9% YoY
|
133.00M
130.29M – 136.63M
+10.6% YoY
|
| EBITDA |
-40.60M
est: -13.21M (-207.4%)
|
-40.74M
est: -37.78M (-7.8%)
|
-38.73M
est: -43.42M (+10.8%)
|
-54.89M
est: -49.89M (-10.0%)
|
-46.74M
est: -55.15M (+15.3%)
|
-63.77M
-64.13M – -63.54M
-15.6% YoY
|
-74.39M
-75.46M – -73.40M
-16.7% YoY
|
-93.37M
-93.48M – -93.27M
-25.5% YoY
|
-117.57M
-120.77M – -115.17M
-25.9% YoY
|
-130.09M
-133.64M – -127.44M
-10.6% YoY
|
| EBIT |
-40.77M
est: -13.24M (-207.9%)
|
-41.15M
est: -39.52M (-4.1%)
|
-39.25M
est: -43.54M (+9.8%)
|
-55.51M
est: -50.02M (-11.0%)
|
-47.50M
est: -55.30M (+14.1%)
|
-63.94M
-64.30M – -63.72M
-15.6% YoY
|
-74.60M
-75.66M – -73.60M
-16.7% YoY
|
-93.62M
-93.73M – -93.52M
-25.5% YoY
|
-117.89M
-121.10M – -115.49M
-25.9% YoY
|
-130.44M
-134.00M – -127.78M
-10.6% YoY
|
| Net Income |
-43.08M
est: -91.44M (+52.9%)
|
-41.43M
est: -39.44M (-5.0%)
|
-41.20M
est: -67.48M (+38.9%)
|
-59.97M
est: -66.47M (+9.8%)
|
-53.31M
est: -53.31M (+0.0%)
|
-53.35M
-56.50M – -48.16M
-0.1% YoY
|
-51.46M
-58.21M – -38.00M
+3.5% YoY
|
-47.32M
-57.51M – -27.16M
+8.1% YoY
|
-35.74M
-37.00M – -34.79M
+24.5% YoY
|
-31.30M
-32.41M – -30.47M
+12.4% YoY
|
| SGA |
27.86M
est: 24.88M (+12.0%)
|
50.05M
est: 41.72M (+20.0%)
|
64.51M
est: 83.00M (-22.3%)
|
91.32M
est: 95.36M (-4.2%)
|
88.47M
est: 105.42M (-16.1%)
|
121.89M
121.47M – 122.59M
+15.6% YoY
|
142.21M
140.31M – 144.24M
+16.7% YoY
|
178.48M
178.28M – 178.68M
+25.5% YoY
|
224.74M
220.15M – 230.86M
+25.9% YoY
|
248.67M
243.60M – 255.45M
+10.6% YoY
|
| EPS |
-2.11
est: -4.05 (+47.9%)
|
-2.02
est: -2.06 (+2.1%)
|
-1.99
est: -2.58 (+22.7%)
|
-2.65
est: -2.56 (-3.6%)
|
-2.04
est: -2.07 (+1.4%)
|
-1.97
-2.17 – -1.85
+4.8% YoY
|
-1.87
-2.23 – -1.46
+5.1% YoY
|
-1.66
-2.20 – -1.04
+11.1% YoY
|
-1.37
-1.42 – -1.33
+17.6% YoY
|
-1.20
-1.24 – -1.17
+12.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-40.37M
OE per share TTM
-1.55
Owner's Yield
-22.13%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
7.1%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
37
Total invested
15.10M
Insider transactions (90d)
0
Beneficial owners (>5%)
18
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EIN: 22-1024240 | 4.11M | 19.60% | — | 4.11M | — | — | CO | New Jersey | 2022-02-07 | ↗ |
| 2 | NEA Partners 10, Limited Partnership | 2.20M | 11.40% | — | 2.20M | — | 2.20M | PN | Delaware | 2021-07-15 | ↗ |
| 3 | New Enterprise Associates 10, Limited Partnership | 2.20M | 11.40% | — | 2.20M | — | 2.20M | PN | Delaware | 2021-07-15 | ↗ |
| 4 | New Enterprise Associates 8A, Limited Partnership | 2.20M | 11.40% | — | 2.20M | — | 2.20M | PN | Delaware | 2021-07-15 | ↗ |
| 5 | Scott D. Sandell | 2.20M | 11.40% | — | 2.20M | — | 2.20M | IN | States | 2021-07-15 | ↗ |
| 6 | Cooperatieve Gilde Healthcare IV U.A. | 1.83M | 9.00% | — | 1.83M | — | 11.00 | OO | — | 2021-07-12 | ↗ |
| 7 | Edwin de Graaf | 1.83M | 9.00% | — | 1.83M | — | 11.00 | IN | — | 2021-07-12 | ↗ |
| 8 | Gilde Healthcare Holding B.V. | 1.83M | 9.00% | — | 1.83M | — | 11.00 | OO | — | 2021-07-12 | ↗ |
| 9 | Gilde Healthcare IV Management B.V. | 1.83M | 9.00% | — | 1.83M | — | 11.00 | OO | — | 2021-07-12 | ↗ |
| 10 | Marc Olivier Perret | 1.83M | 9.00% | — | 1.83M | — | 11.00 | IN | — | 2021-07-12 | ↗ |
| 11 | Martemanshurk B.V. (100% owned by Pieter van der Meer) | 1.83M | 9.00% | — | 1.83M | — | 11.00 | OO | — | 2021-07-12 | ↗ |
| 12 | Kirk Nielsen | 1.46M | 7.20% | — | 1.46M | — | 1.46M | IN | United States of America | 2022-02-10 | ↗ |
| 13 | Peter Justin Klein | 1.46M | 7.20% | — | 1.46M | — | 1.46M | IN | United States of America | 2022-02-10 | ↗ |
| 14 | Vensana Capital I GP, LLC | 1.46M | 7.20% | — | 1.46M | — | 1.46M | OO | United States of America | 2022-02-10 | ↗ |
| 15 | Vensana Capital I, L.P. | 1.46M | 7.20% | — | 1.46M | — | 1.46M | PN | United States of America | 2022-02-10 | ↗ |
| 16 | 2 | 1.04M | 5.10% | — | 1.04M | — | 1.04M | OO | Cayman Islands | 2022-04-29 | ↗ |
| 17 | GlaxoSmithKline plc | 1.01M | 5.00% | 1.01M | — | 1.01M | 1.01M | CO | England and Wales | 2021-07-12 | ↗ |
| 18 | GSK plc | 1.01M | 4.90% | 1.01M | — | 1.01M | 1.01M | CO | England and Wales | 2023-02-06 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
37
-53 vs prev Q
New positions
12
Closed positions
65
Increased
23
Reduced
3
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | JOHNSON & JOHNSON | 4.02M -78.6K (-1.9%) | 28.58M -4.5M (-13.7%) | 15.35% -0.388 pp | 5.15% -1.389 pp | USD16.75 -57.6% | 18 qtrs — |
| 2 | NEA MANAGEMENT COMPANY, LLC | 2.03M +— (+0.0%) | 14.39M -2.0M (-12.0%) | 7.77% -0.004 pp | 0.73% -0.164 pp | USD28.00 -74.6% | 19 qtrs — |
| 3 | VANGUARD GROUP INC | 1.12M +30.4K (+2.8%) | 7.96M -841.4K (-9.6%) | 4.27% +0.093 pp | 0.00% +0.000 pp | USD12.97 -45.3% | 19 qtrs — |
| 4 | BLACKROCK, INC. | 1.06M +45.4K (+4.5%) | 7.53M -662.9K (-8.1%) | 4.05% +0.151 pp | 0.00% +0.000 pp | USD8.99 -21.0% | 6 qtrs — |
| 5 | GSK PLC | 1.01M +1.0M (+100.0%) | 7.15M +7.2M (+100.0%) | 3.85% +3.850 pp | 0.90% +0.895 pp | USD7.10 +0.0% | 1 qtrs NEW |
| 6 | BALYASNY ASSET MANAGEMENT L.P. | 814.9K +118.7K (+17.0%) | 5.79M +167.3K (+3.0%) | 3.12% +0.454 pp | 0.01% +0.000 pp | USD9.34 -24.0% | 12 qtrs — |
| 7 | SILVERCREST ASSET MANAGEMENT GROUP LLC | 634.6K +275.3K (+76.6%) | 4.51M +1.6M (+55.4%) | 2.43% +1.055 pp | 0.03% +0.012 pp | USD10.25 -30.7% | 9 qtrs — |
| 8 | PARKMAN HEALTHCARE PARTNERS LLC | 413.0K -78.4K (-16.0%) | 2.93M -1.0M (-26.1%) | 1.58% -0.302 pp | 0.28% -0.135 pp | USD12.88 -44.9% | 11 qtrs — |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 403.9K -1.0K (-0.2%) | 2.87M -399.4K (-12.2%) | 1.54% -0.013 pp | 0.00% +0.000 pp | USD13.17 -46.1% | 18 qtrs — |
| 10 | MORGAN STANLEY | 380.6K -50.9K (-11.8%) | 2.70M -780.1K (-22.4%) | 1.45% -0.204 pp | 0.00% +0.000 pp | USD11.46 -38.0% | 18 qtrs — |
| 11 | STATE STREET CORP | 311.7K +16.3K (+5.5%) | 2.21M -171.0K (-7.2%) | 1.19% +0.056 pp | 0.00% +0.000 pp | USD13.84 -48.7% | 18 qtrs — |
| 12 | CITADEL ADVISORS LLC | 305.5K +259.5K (+563.4%) | 2.17M +1.8M (+483.6%) | 1.17% +0.989 pp | 0.00% +0.000 pp | USD7.69 -7.7% | 13 qtrs — |
| 13 | GSA CAPITAL PARTNERS LLP | 183.5K -36.9K (-16.7%) | 1.30M -476.0K (-26.8%) | 0.70% -0.144 pp | 0.11% -0.036 pp | USD7.21 -1.5% | 4 qtrs — |
| 14 | FOURWORLD CAPITAL MANAGEMENT LLC | 180.0K +35.0K (+24.1%) | 1.28M +107.9K (+9.2%) | 0.69% +0.134 pp | 1.04% -0.811 pp | USD7.05 +0.7% | 8 qtrs — |
| 15 | GOLDMAN SACHS GROUP INC | 177.6K -24.5K (-12.1%) | 1.26M -369.7K (-22.7%) | 0.68% -0.098 pp | 0.00% +0.000 pp | USD10.29 -31.0% | 12 qtrs — |
| 16 | TUDOR INVESTMENT CORP ET AL | 157.3K +31.2K (+24.8%) | 1.12M +99.2K (+9.8%) | 0.60% +0.119 pp | 0.00% +0.000 pp | USD11.74 -39.5% | 8 qtrs — |
| 17 | MAIRS & POWER INC | 142.5K -2.5K (-1.7%) | 1.01M -158.4K (-13.5%) | 0.54% -0.013 pp | 0.01% -0.001 pp | USD12.28 -42.2% | 17 qtrs — |
| 18 | MILLENNIUM MANAGEMENT LLC | 139.2K -87.5K (-38.6%) | 988.3K -841.3K (-46.0%) | 0.53% -0.339 pp | 0.00% 0.000 pp | USD9.43 -24.7% | 19 qtrs — |
| 19 | NORTHERN TRUST CORP | 137.8K -11.5K (-7.7%) | 978.4K -226.3K (-18.8%) | 0.53% -0.044 pp | 0.00% +0.000 pp | USD13.74 -48.3% | 18 qtrs — |
| 20 | D. E. SHAW & CO., INC. | 96.2K +19.8K (+25.9%) | 683.1K +66.2K (+10.7%) | 0.37% +0.076 pp | 0.00% +0.000 pp | USD9.60 -26.0% | 13 qtrs — |
| 21 | UBS GROUP AG | 88.4K -62.9K (-41.6%) | 627.6K -593.5K (-48.6%) | 0.34% -0.243 pp | 0.00% 0.000 pp | USD10.75 -34.0% | 19 qtrs — |
| 22 | QUANTINNO CAPITAL MANAGEMENT LP | 76.0K +8.9K (+13.3%) | 539.4K -1.7K (-0.3%) | 0.29% +0.034 pp | 0.00% 0.000 pp | USD7.41 -4.2% | 3 qtrs — |
| 23 | CRESSET ASSET MANAGEMENT, LLC | 71.8K +— (+0.0%) | 509.8K -69.6K (-12.0%) | 0.28% 0.000 pp | 0.00% 0.000 pp | USD19.98 -64.5% | 9 qtrs — |
| 24 | QUEST PARTNERS LLC | 70.8K +62.3K (+734.2%) | 502.6K +434.2K (+633.9%) | 0.27% +0.238 pp | 0.03% +0.024 pp | USD7.30 -2.7% | 8 qtrs — |
| 25 | BNP PARIBAS ARBITRAGE, SNC | 62.6K +5.2K (+9.0%) | 444.5K -19.1K (-4.1%) | 0.24% +0.018 pp | 0.00% +0.000 pp | USD11.75 -39.6% | 5 qtrs — |
| 26 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 54.0K +— (+0.0%) | 383.4K -52.4K (-12.0%) | 0.21% -0.001 pp | 0.01% -0.001 pp | USD8.75 -18.9% | 6 qtrs — |
| 27 | DIMENSIONAL FUND ADVISORS LP | 53.2K +356.0 (+0.7%) | 377.7K -48.3K (-11.3%) | 0.20% +0.001 pp | 0.00% +0.000 pp | USD8.76 -18.9% | 7 qtrs — |
| 28 | SCHONFELD STRATEGIC ADVISORS LLC | 50.0K -10.1K (-16.8%) | 354.9K -129.7K (-26.8%) | 0.19% -0.039 pp | 0.00% -0.001 pp | USD12.77 -44.4% | 11 qtrs — |
| 29 | MARSHALL WACE, LLP | 49.8K +33.7K (+208.5%) | 353.8K +223.4K (+171.4%) | 0.19% +0.128 pp | 0.00% +0.000 pp | USD7.21 -1.5% | 9 qtrs — |
| 30 | WEXFORD CAPITAL LP | 48.1K +2.0K (+4.4%) | 341.6K -30.2K (-8.1%) | 0.18% +0.008 pp | 0.07% +0.013 pp | USD8.03 -11.6% | 2 qtrs — |
| 31 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 45.9K +9.0 (+0.0%) | 326.2K -44.5K (-12.0%) | 0.18% -0.001 pp | 0.00% +0.000 pp | USD13.56 -47.6% | 11 qtrs — |
| 32 | BANK OF AMERICA CORP /DE/ | 44.5K -135.9K (-75.3%) | 315.9K -1.1M (-78.3%) | 0.17% -0.522 pp | 0.00% 0.000 pp | USD9.40 -24.5% | 18 qtrs — |
| 33 | NUVEEN, LLC | 42.3K -27.0K (-38.9%) | 300.3K -258.6K (-46.3%) | 0.16% -0.104 pp | 0.00% 0.000 pp | USD10.61 -33.1% | 4 qtrs — |
| 34 | BANK OF NEW YORK MELLON CORP | 35.9K -1.9K (-5.1%) | 254.8K -50.4K (-16.5%) | 0.14% -0.008 pp | 0.00% +0.000 pp | USD14.08 -49.6% | 11 qtrs — |
| 35 | MASSAR CAPITAL MANAGEMENT, LP | 34.6K +— (+0.0%) | 245.7K -33.6K (-12.0%) | 0.13% -0.001 pp | 0.03% -0.010 pp | USD8.07 -12.0% | 4 qtrs — |
| 36 | BARCLAYS PLC | 25.3K +6.2K (+32.5%) | 179.4K +11.4K (+6.8%) | 0.10% +0.023 pp | 0.00% +0.000 pp | USD9.48 -25.1% | 12 qtrs — |
| 37 | TWO SIGMA INVESTMENTS, LP | 24.5K -10.9K (-30.9%) | 173.6K -112.0K (-39.2%) | 0.09% -0.043 pp | 0.00% 0.000 pp | USD11.59 -38.7% | 12 qtrs — |
| 38 | JPMORGAN CHASE & CO | 24.4K -9.2K (-27.4%) | 173.0K -97.9K (-36.1%) | 0.09% -0.036 pp | 0.00% +0.000 pp | USD12.71 -44.1% | 11 qtrs — |
| 39 | STONERIDGE INVESTMENT PARTNERS LLC | 23.6K +3.5K (+17.5%) | 168.0K +6.0K (+3.7%) | 0.09% +0.013 pp | 0.12% +0.006 pp | USD6.20 +14.5% | 3 qtrs — |
| 40 | POINT72 ASSET MANAGEMENT, L.P. | 23.4K +23.4K (+100.0%) | 166.3K +166.3K (+100.0%) | 0.09% +0.090 pp | 0.00% +0.000 pp | USD7.10 +0.0% | 1 qtrs NEW |
| 41 | DEUTSCHE BANK AG\ | 21.3K +11.7K (+122.9%) | 151.2K +74.1K (+96.1%) | 0.08% +0.045 pp | 0.00% +0.000 pp | USD8.38 -15.3% | 11 qtrs — |
| 42 | WELLS FARGO & COMPANY/MN | 20.3K +7.7K (+61.3%) | 143.9K +42.5K (+41.9%) | 0.08% +0.029 pp | 0.00% +0.000 pp | USD10.73 -33.8% | 19 qtrs — |
| 43 | RBF CAPITAL, LLC | 20.0K +— (+0.0%) | 142.0K -19.4K (-12.0%) | 0.08% 0.000 pp | 0.01% -0.001 pp | USD9.33 -23.9% | 14 qtrs — |
| 44 | RHUMBLINE ADVISERS | 20.0K -972.0 (-4.6%) | 141.8K -27.2K (-16.1%) | 0.08% -0.004 pp | 0.00% +0.000 pp | USD13.71 -48.2% | 11 qtrs — |
| 45 | ALLIANCEBERNSTEIN L.P. | 17.6K +— (+0.0%) | 124.7K -17.0K (-12.0%) | 0.07% 0.000 pp | 0.00% +0.000 pp | USD11.36 -37.5% | 7 qtrs — |
| 46 | INSCRIPTION CAPITAL, LLC | 17.5K +283.0 (+1.6%) | 124.5K -14.7K (-10.6%) | 0.07% +0.001 pp | 0.01% -0.002 pp | USD8.05 -11.8% | 2 qtrs — |
| 47 | GRAHAM CAPITAL MANAGEMENT, L.P. | 17.3K -4.5K (-20.8%) | 122.9K -53.4K (-30.3%) | 0.07% -0.018 pp | 0.00% +0.000 pp | USD8.07 -12.0% | 2 qtrs — |
| 48 | PERKINS CAPITAL MANAGEMENT INC | 16.2K -3.6K (-18.2%) | 114.7K -44.7K (-28.1%) | 0.06% -0.014 pp | 0.09% -0.049 pp | USD6.26 +13.4% | 3 qtrs — |
| 49 | CENTIVA CAPITAL, LP | 15.1K +15.1K (+100.0%) | 107.4K +107.4K (+100.0%) | 0.06% +0.058 pp | 0.00% +0.001 pp | USD7.10 +0.0% | 1 qtrs NEW |
| 50 | PHILADELPHIA TRUST CO | 15.0K +— (+0.0%) | 107.0K -14.0K (-11.6%) | 0.06% 0.000 pp | 0.01% -0.001 pp | USD5.88 +20.7% | 3 qtrs — |
| 51 | XTX TOPCO LTD | 12.7K +12.7K (+100.0%) | 89.9K +89.9K (+100.0%) | 0.05% +0.048 pp | 0.00% +0.002 pp | USD7.10 +0.0% | 3 qtrs — |
| 52 | CI PRIVATE WEALTH, LLC | 11.4K +11.4K (+100.0%) | 81.1K +81.1K (+100.0%) | 0.04% +0.044 pp | 0.00% +0.000 pp | USD7.10 +0.0% | 1 qtrs NEW |
| 53 | MITSUBISHI UFJ KOKUSAI ASSET MANAGEMENT CO., LTD. | 11.3K -16.6K (-59.4%) | 80.2K -144.5K (-64.3%) | 0.04% -0.064 pp | 0.00% 0.000 pp | USD8.83 -19.6% | 11 qtrs — |
| 54 | VIRTU FINANCIAL LLC | 11.2K +11.2K (+100.0%) | 79.0K +79.0K (+100.0%) | 0.04% +0.043 pp | 0.00% +0.003 pp | USD7.10 +0.0% | 1 qtrs NEW |
| 55 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 10.6K -41.7K (-79.8%) | 75.0K -346.4K (-82.2%) | 0.04% -0.160 pp | 0.00% +0.000 pp | USD11.28 -37.1% | 9 qtrs — |
| 56 | ROYAL BANK OF CANADA | 10.6K -25.2K (-70.3%) | 75.0K -214.0K (-74.0%) | 0.04% -0.097 pp | 0.00% +0.000 pp | USD8.49 -16.4% | 18 qtrs — |
| 57 | R SQUARED LTD | 10.4K +10.4K (+100.0%) | 74.1K +74.1K (+100.0%) | 0.04% +0.040 pp | 0.03% +0.035 pp | USD7.10 +0.0% | 1 qtrs NEW |
| 58 | KESTRA ADVISORY SERVICES, LLC | 9.9K -4.9K (-33.0%) | 70.5K -49.2K (-41.1%) | 0.04% -0.019 pp | 0.00% 0.000 pp | USD13.29 -46.6% | 10 qtrs — |
| 59 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 7.5K -80.0 (-1.1%) | 53.2K -7.9K (-12.9%) | 0.03% 0.000 pp | 0.00% +0.000 pp | USD11.00 -35.5% | 7 qtrs — |
| 60 | WHITTIER TRUST CO | 6.0K +— (+0.0%) | 47.5K -4.7K (-9.1%) | 0.02% 0.000 pp | 0.00% 0.000 pp | USD12.23 -41.9% | 4 qtrs — |
| 61 | LARSON FINANCIAL GROUP LLC | 5.4K +3.3K (+155.6%) | 38.5K +21.4K (+124.9%) | 0.02% +0.013 pp | 0.00% +0.001 pp | USD8.85 -19.8% | 4 qtrs — |
| 62 | GROUP ONE TRADING, L.P. | 5.4K +5.4K (+100.0%) | 38.5K +38.5K (+100.0%) | 0.02% +0.021 pp | 0.00% +0.000 pp | USD7.10 +0.0% | 3 qtrs — |
| 63 | NEW YORK STATE COMMON RETIREMENT FUND | 4.2K +— (+0.0%) | 29.8K -4.1K (-12.0%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD15.50 -54.2% | 11 qtrs — |
| 64 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 3.8K +— (+0.0%) | 26.8K -3.7K (-12.0%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD12.67 -44.0% | 5 qtrs — |
| 65 | HIGHMARK WEALTH MANAGEMENT LLC | 3.0K +— (+0.0%) | 21.3K -2.9K (-12.0%) | 0.01% +0.000 pp | 0.01% -0.002 pp | USD8.81 -19.4% | 11 qtrs — |
| 66 | TOWER RESEARCH CAPITAL LLC (TRC) | 2.3K +546.0 (+31.6%) | 16.2K +2.2K (+15.8%) | 0.01% +0.002 pp | 0.00% +0.000 pp | USD8.09 -12.2% | 18 qtrs — |
| 67 | LEGAL & GENERAL GROUP PLC | 1.6K -106.0 (-6.1%) | 11.5K -2.4K (-17.4%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD13.20 -46.2% | 11 qtrs — |
| 68 | GAMMA INVESTING LLC | 1.6K -51.0 (-3.2%) | 11.1K -1.9K (-14.8%) | 0.01% 0.000 pp | 0.00% 0.000 pp | USD8.08 -12.1% | 8 qtrs — |
| 69 | RUSSELL INVESTMENTS GROUP, LTD. | 1.3K +— (+0.0%) | 9.5K -1.3K (-12.0%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD8.07 -12.0% | 5 qtrs — |
| 70 | ADVISOR GROUP HOLDINGS, INC. | 1.0K -564.0 (-36.1%) | 7.1K -5.4K (-43.2%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD7.89 -10.0% | 18 qtrs — |
| 71 | JNBA FINANCIAL ADVISORS | 1.0K +— (+0.0%) | 7.1K -970.0 (-12.0%) | 0.00% +0.000 pp | 0.00% 0.000 pp | USD8.81 -19.4% | 6 qtrs — |
| 72 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 988.00 -13.0 (-1.3%) | 7.0K -1.1K (-13.2%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD15.16 -53.2% | 11 qtrs — |
| 73 | AMERITAS INVESTMENT PARTNERS, INC. | 918.00 +— (+0.0%) | 6.5K -890.0 (-12.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD15.44 -54.0% | 11 qtrs — |
| 74 | AMALGAMATED BANK | 505.00 -10.0 (-1.9%) | 4.0K +— (+0.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD14.56 -51.2% | 11 qtrs — |
| 75 | VERSANT CAPITAL MANAGEMENT, INC | 475.00 +220.0 (+86.3%) | 3.4K +1.3K (+63.9%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD6.44 +10.2% | 3 qtrs — |
| 76 | CITIGROUP INC | 365.00 -357.0 (-49.4%) | 2.6K -3.2K (-55.5%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD13.10 -45.8% | 18 qtrs — |
| 77 | FMR LLC | 301.00 +12.0 (+4.2%) | 2.1K -195.0 (-8.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD13.49 -47.4% | 16 qtrs — |
| 78 | OPTIVER HOLDING B.V. | 272.00 +— (+0.0%) | 1.9K -264.0 (-12.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.07 -12.0% | 2 qtrs — |
| 79 | JONES FINANCIAL COMPANIES LLLP | 250.00 +— (+0.0%) | 1.8K -113.0 (-6.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD12.23 -41.9% | 4 qtrs — |
| 80 | ARCHER INVESTMENT CORP | 250.00 +— (+0.0%) | 1.8K -243.0 (-12.0%) | 0.00% +0.000 pp | 0.00% 0.000 pp | USD11.71 -39.4% | 7 qtrs — |
| 81 | THURSTON, SPRINGER, MILLER, HERD & TITAK, INC. | 225.00 +— (+0.0%) | 1.6K -218.0 (-12.0%) | 0.00% +0.000 pp | 0.00% -0.003 pp | USD10.08 -29.6% | 7 qtrs — |
| 82 | NISA INVESTMENT ADVISORS, LLC | 159.00 +— (+0.0%) | 1.1K -154.0 (-12.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD7.47 -5.0% | 8 qtrs — |
| 83 | PHYSICIAN WEALTH ADVISORS, INC. | 149.00 +— (+0.0%) | 1.1K -145.0 (-12.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD5.88 +20.7% | 3 qtrs — |
| 84 | STERLING CAPITAL MANAGEMENT LLC | 104.00 +65.0 (+166.7%) | 738.00 +423.0 (+134.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD7.11 -0.1% | 6 qtrs — |
| 85 | EVERSOURCE WEALTH ADVISORS, LLC | 25.00 -4.0 (-13.8%) | 178.00 -56.0 (-23.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.04 -11.7% | 2 qtrs — |
| 86 | SBI SECURITIES CO., LTD. | 12.00 -1.0 (-7.7%) | 85.00 -20.0 (-19.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD12.25 -42.0% | 5 qtrs — |
| 87 | SUNBELT SECURITIES, INC. | 11.00 +— (+0.0%) | 78.00 -11.0 (-12.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.00 -11.3% | 2 qtrs — |
| 88 | PNC FINANCIAL SERVICES GROUP, INC. | 5.00 +5.0 (+100.0%) | 36.00 +36.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD7.00 +1.4% | 1 qtrs NEW |
| 89 | SRS CAPITAL ADVISORS, INC. | 2.00 -154.0 (-98.7%) | 14.00 -1.2K (-98.9%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD8.00 -11.3% | 2 qtrs — |
| 90 | US BANCORP \DE\ | — -500.0 (-100.0%) | — -4.0K (-100.0%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD— | 18 qtrs SOLD |
| 91 | JANE STREET GROUP, LLC | — -14.2K (-100.0%) | — -114.6K (-100.0%) | 0.00% -0.055 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 92 | CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD | — -2.0 (-100.0%) | — -16.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 93 | ARCHON CAPITAL MANAGEMENT LLC | — -144.0K (-100.0%) | — -1.2M (-100.0%) | 0.00% -0.552 pp | 0.00% -0.692 pp | USD— | 9 qtrs SOLD |
| 94 | SIMPLEX TRADING, LLC | — -16.3K (-100.0%) | — -131.0K (-100.0%) | 0.00% -0.063 pp | 0.00% 0.000 pp | USD— | 9 qtrs SOLD |
| 95 | LPL FINANCIAL LLC | — -18.8K (-100.0%) | — -151.9K (-100.0%) | 0.00% -0.072 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 96 | TWO SIGMA ADVISERS, LP | — -20.8K (-100.0%) | — -167.9K (-100.0%) | 0.00% -0.080 pp | 0.00% 0.000 pp | USD— | 4 qtrs SOLD |
| 97 | MAREX GROUP PLC | — -15.0K (-100.0%) | — -121.1K (-100.0%) | 0.00% -0.058 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 98 | EHP FUNDS INC. | — -33.8K (-100.0%) | — -273.1K (-100.0%) | 0.00% -0.130 pp | 0.00% -0.241 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 45 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.02% | 280.2K | 0.60% |
| 2 | iShares Russell 2000 Growth ETF IWO | 0.01% | 849.3K | 0.24% |
| 3 | Vanguard Russell 2000 Growth ETF VTWG | 0.00% | 81.6K | 0.06% |
| 4 | State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc) R2US.L | 0.00% | 149.9K | 0.30% |
| 5 | Global X - Russell 2000 ETF RSSL | 0.00% | 39.0K | 0.08% |
| 6 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.00% | 8.4K | 0.25% |
| 7 | Vanguard Russell 2000 ETF VTWO | 0.00% | 446.3K | 0.06% |
| 8 | iShares Russell 2000 BuyWrite ETF IWMW | 0.00% | 1.4K | 0.39% |
| 9 | iShares Russell 2000 ETF IWM | 0.00% | 2.06M | 0.19% |
| 10 | iShares U.S. Small Cap Index ETF (CAD-Hedged) XSU.TO | 0.00% | 13.4K | 0.36% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
3.50
Bullish
Ratio by volume
3.00
Bullish
Buys
14
Sells
4
Shares acquired
1.02M
Shares disposed
14.8K
Cash buys
2.00
Cash sales
4.00
Net activity
+1,007,145
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-02 | VERRASTRO PAUL | Officer | S-Sale | D | Common Stock | 1,284 | 7.90 | 10.1K | 60,551 | D | ↗ |
| 2026-03-02 | OASHEIM JARED | Officer | S-Sale | D | Common Stock | 1,744 | 7.90 | 13.8K | 96,703 | D | ↗ |
| 2026-03-02 | Morrison Gregory | Officer | A-Award | A | Stock Option (right to buy) | 154,500 | 8.22 | 1.27M | 154,500 | D | ↗ |
| 2026-03-02 | John Robert Allen | Officer | S-Sale | D | Common Stock | 3,964 | 7.90 | 31.3K | 86,036 | D | ↗ |
| 2026-03-02 | Hykes Kevin | Director / Officer | S-Sale | D | Common Stock | 7,763 | 7.90 | 61.3K | 284,237 | D | ↗ |
| 2026-03-02 | Adamson Philip B. | Officer | S-Sale | D | Common Stock | 1,262 | 7.90 | 10.0K | 61,578 | D | ↗ |
| 2026-02-27 | VERRASTRO PAUL | Officer | A-Award | A | Common Stock | 45,000 | 0.00 | — | 61,835 | D | ↗ |
| 2026-02-27 | OASHEIM JARED | Officer | A-Award | A | Stock Option (right to buy) | 91,000 | 8.16 | 742.6K | 91,000 | D | ↗ |
| 2026-02-27 | John Robert Allen | Officer | A-Award | A | Stock Option (right to buy) | 52,000 | 8.16 | 424.3K | 52,000 | D | ↗ |
| 2026-02-27 | Hykes Kevin | Director / Officer | A-Award | A | Stock Option (right to buy) | 238,000 | 8.16 | 1.94M | 238,000 | D | ↗ |
| 2026-02-27 | Binkowski Brent | Officer | A-Award | A | Stock Option (right to buy) | 23,000 | 8.16 | 187.7K | 23,000 | D | ↗ |
| 2026-02-27 | Adamson Philip B. | Officer | A-Award | A | Common Stock | 41,000 | 0.00 | — | 62,840 | D | ↗ |
| 2026-02-20 | Jain Mudit K. | Director | P-Purchase | A | Common Stock | 46,800 | 6.36 | 297.6K | 980,183 | I | ↗ |
| 2026-02-18 | Jain Mudit K. | Director | P-Purchase | A | Common Stock | 600 | 4.64 | 2.8K | 5,650 | D | ↗ |
| 2025-11-26 | JOHNSON & JOHNSON | 10% Owner | S-Sale | D | Common Stock | 6,337 | 10.03 | 63.6K | 4,024,861 | I | ↗ |
| 2025-11-25 | JOHNSON & JOHNSON | 10% Owner | S-Sale | D | Common Stock | 16,000 | 10.03 | 160.5K | 4,031,198 | I | ↗ |
| 2025-11-24 | JOHNSON & JOHNSON | 10% Owner | S-Sale | D | Common Stock | 2,200 | 10.06 | 22.1K | 4,047,198 | I | ↗ |
| 2025-11-21 | JOHNSON & JOHNSON | 10% Owner | S-Sale | D | Common Stock | 500 | 10.00 | 5.0K | 4,049,398 | I | ↗ |
| 2025-11-12 | JOHNSON & JOHNSON | 10% Owner | S-Sale | D | Common Stock | 1,000 | 10.00 | 10.0K | 4,049,898 | I | ↗ |
| 2025-11-07 | JOHNSON & JOHNSON | 10% Owner | S-Sale | D | Common Stock | 200 | 10.00 | 2.0K | 4,050,898 | I | ↗ |
| 2025-11-06 | JOHNSON & JOHNSON | 10% Owner | S-Sale | D | Common Stock | 52,332 | 10.21 | 534.3K | 4,051,098 | I | ↗ |
| 2025-08-11 | Binkowski Brent | Officer | A-Award | A | Stock Option (right to buy) | 74,900 | 7.51 | 562.5K | 74,900 | D | ↗ |
| 2025-06-03 | SLATTERY JOSEPH P | Director | A-Award | A | Stock Option (right to buy) | 19,554 | 6.76 | 132.2K | 19,554 | D | ↗ |
| 2025-06-03 | SHADAN MARTHA | Director | A-Award | A | Stock Option (right to buy) | 19,554 | 6.76 | 132.2K | 19,554 | D | ↗ |
| 2025-06-03 | Nielsen Kirk G. | Director | A-Award | A | Stock Option (right to buy) | 19,554 | 6.76 | 132.2K | 19,554 | D | ↗ |
| 2025-06-03 | Jain Mudit K. | Director | A-Award | A | Stock Option (right to buy) | 19,554 | 6.76 | 132.2K | 19,554 | D | ↗ |
| 2025-06-03 | Hill, Mitch C. | Director | A-Award | A | Stock Option (right to buy) | 19,554 | 6.76 | 132.2K | 19,554 | D | ↗ |
| 2025-06-03 | Ballinger Kevin J. | Director | A-Award | A | Stock Option (right to buy) | 19,554 | 6.76 | 132.2K | 19,554 | D | ↗ |
| 2025-05-15 | Nielsen Kirk G. | Director | P-Purchase | A | Common Stock | 10,966 | 5.45 | 59.8K | 1,910,134 | I | ↗ |
| 2025-05-14 | Nielsen Kirk G. | Director | P-Purchase | A | Common Stock | 61,200 | 5.23 | 320.4K | 1,899,168 | I | ↗ |
| 2025-05-13 | Nielsen Kirk G. | Director | P-Purchase | A | Common Stock | 101,413 | 5.29 | 536.3K | 1,837,968 | I | ↗ |
| 2025-05-13 | Jain Mudit K. | Director | P-Purchase | A | Common Stock | 150 | 5.26 | 789.00 | 5,050 | D | ↗ |
| 2025-05-12 | Nielsen Kirk G. | Director | P-Purchase | A | Common Stock | 25,200 | 4.79 | 120.7K | 1,736,555 | I | ↗ |
| 2025-05-12 | Jain Mudit K. | Director | P-Purchase | A | Common Stock | 1,500 | 4.66 | 7.0K | 4,900 | D | ↗ |
| 2025-05-12 | Hykes Kevin | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 4.84 | 24.2K | 133,000 | D | ↗ |
| 2025-02-28 | VERRASTRO PAUL | Officer | A-Award | A | Common Stock | 16,000 | 0.00 | — | 16,835 | D | ↗ |
| 2025-02-28 | OASHEIM JARED | Officer | A-Award | A | Common Stock | 22,000 | 0.00 | — | 37,447 | D | ↗ |
| 2025-02-28 | John Robert Allen | Officer | A-Award | A | Stock Option (right to buy) | 38,000 | 12.96 | 492.5K | 38,000 | D | ↗ |
| 2025-02-28 | Hykes Kevin | Director / Officer | A-Award | A | Common Stock | 98,000 | 0.00 | — | 128,000 | D | ↗ |
| 2025-02-28 | Adamson Philip B. | Officer | A-Award | A | Stock Option (right to buy) | 30,000 | 12.96 | 388.8K | 30,000 | D | ↗ |
| 2025-02-04 | Adamson Philip B. | Officer | — | — | Stock Option (right to buy) | 190,208 | 7.82 | 1.49M | 0 | D | ↗ |
| 2024-11-21 | VERRASTRO PAUL | Officer | G-Gift | D | Common Stock | 1,040 | 0.00 | — | 835 | D | ↗ |
| 2024-11-19 | VERRASTRO PAUL | Officer | M-Exempt | D | Stock Option (right to buy) | 2,500 | 5.14 | 12.9K | 73,306 | D | ↗ |
| 2024-09-03 | Hill, Mitch C. | Director | A-Award | A | Stock Option (right to buy) | 36,136 | 9.05 | 327.0K | 36,136 | — | ↗ |
| 2024-09-03 | Ballinger Kevin J. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-08-15 | SLATTERY JOSEPH P | Director | P-Purchase | A | Common Stock | 3,000 | 8.10 | 24.3K | 30,645 | — | ↗ |
| 2024-08-08 | SLATTERY JOSEPH P | Director | P-Purchase | A | Common Stock | 3,000 | 8.24 | 24.7K | 27,645 | — | ↗ |
| 2024-08-06 | SLATTERY JOSEPH P | Director | P-Purchase | A | Common Stock | 2,500 | 9.09 | 22.7K | 24,645 | — | ↗ |
| 2024-08-05 | Hykes Kevin | Director / Officer | P-Purchase | A | Common Stock | 30,000 | 8.36 | 250.8K | 30,000 | — | ↗ |
| 2024-07-31 | Hykes Kevin | Director / Officer | A-Award | A | Stock Option (right to buy) | 180,000 | 8.55 | 1.54M | 180,000 | — | ↗ |
| 2024-06-27 | John Robert Allen | Officer | A-Award | A | Stock Option (right to buy) | 122,192 | 11.70 | 1.43M | 122,192 | — | ↗ |
| 2024-06-04 | SLATTERY JOSEPH P | Director | A-Award | A | Stock Option (right to buy) | 20,961 | 6.49 | 136.0K | 20,961 | — | ↗ |
| 2024-06-04 | SHADAN MARTHA | Director | A-Award | A | Stock Option (right to buy) | 27,250 | 6.49 | 176.9K | 27,250 | — | ↗ |
| 2024-06-04 | Nielsen Kirk G. | Director | A-Award | A | Stock Option (right to buy) | 20,961 | 6.49 | 136.0K | 20,961 | — | ↗ |
| 2024-06-04 | Jain Mudit K. | Director | A-Award | A | Stock Option (right to buy) | 20,961 | 6.49 | 136.0K | 20,961 | — | ↗ |
| 2024-06-04 | Behbahani Ali | Director | A-Award | A | Stock Option (right to buy) | 20,961 | 6.49 | 136.0K | 20,961 | — | ↗ |
| 2024-03-25 | Palmer Craig E. | Officer | M-Exempt | A | Common Stock | 404 | 0.24 | 95.75 | 1,078 | — | ↗ |
| 2024-02-29 | JOHNSON & JOHNSON | 10% Owner | M-Exempt | A | Common Stock | 85 | 0.24 | 20.15 | 4,100,384 | — | ↗ |
| 2024-02-23 | VERRASTRO PAUL | Officer | G-Gift | D | Common Stock | 1,650 | 0.00 | — | 805 | — | ↗ |
| 2024-02-20 | VERRASTRO PAUL | Officer | S-Sale | D | Common Stock | 2,545 | 21.91 | 55.7K | 2,455 | — | ↗ |
| 2024-02-16 | JOHNSON & JOHNSON | 10% Owner | X-InTheMoney | D | Warrant to Purchase Common Stock | 607,225 | 0.16 | 95.9K | 0 | — | ↗ |
| 2024-02-12 | Hykes Kevin | Director / Officer | A-Award | A | Stock Option (right to buy) | 360,000 | 23.61 | 8.50M | 360,000 | — | ↗ |
| 2024-02-02 | Yared Nadim | Director / Officer | A-Award | A | Stock Option (right to buy) | 22,050 | 24.42 | 538.5K | 22,050 | — | ↗ |
| 2024-02-02 | VERRASTRO PAUL | Officer | A-Award | A | Stock Option (right to buy) | 32,000 | 24.42 | 781.4K | 32,000 | — | ↗ |
| 2024-02-02 | Palmer Craig E. | Officer | A-Award | A | Stock Option (right to buy) | 31,600 | 24.42 | 771.7K | 31,600 | — | ↗ |
| 2024-02-02 | OASHEIM JARED | Officer | A-Award | A | Stock Option (right to buy) | 55,500 | 24.42 | 1.36M | 55,500 | — | ↗ |
| 2024-01-29 | Yared Nadim | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 4,055 | 0.24 | 961.04 | 0 | — | ↗ |
| 2023-12-28 | SLATTERY JOSEPH P | Director | M-Exempt | A | Common Stock | 224 | 0.24 | 53.09 | 20,419 | — | ↗ |
| 2023-12-14 | Behbahani Ali | Director | M-Exempt | A | Common Stock | 316 | 0.24 | 74.89 | 316 | — | ↗ |
| 2023-10-16 | Galle Liz | Officer | M-Exempt | A | Common Stock | 778 | 0.24 | 184.39 | 778 | — | ↗ |
| 2023-09-18 | OASHEIM JARED | Officer | M-Exempt | D | Stock Option (right to buy) | 527 | 0.24 | 124.90 | 0 | — | ↗ |
| 2023-09-15 | Johnson & Johnson Innovation - JJDC, Inc. | 10% Owner | — | D | Stock Option (Right to Buy) | 300 | 0.24 | 71.10 | 0 | — | ↗ |
| 2023-08-03 | VERRASTRO PAUL | Officer | S-Sale | D | Common Stock | 628 | 18.55 | 11.7K | 0 | — | ↗ |
| 2023-08-02 | VERRASTRO PAUL | Officer | G-Gift | D | Common Stock | 2,000 | 0.00 | — | 628 | — | ↗ |
| 2023-07-31 | VERRASTRO PAUL | Officer | S-Sale | D | Common Stock | 1,122 | 17.49 | 19.6K | 2,628 | — | ↗ |
| 2023-06-05 | SLATTERY JOSEPH P | Director | A-Award | A | Stock Option (right to buy) | 12,012 | 12.33 | 148.1K | 12,012 | — | ↗ |
| 2023-06-05 | SHADAN MARTHA | Director | A-Award | A | Stock Option (right to buy) | 12,012 | 12.33 | 148.1K | 12,012 | — | ↗ |
| 2023-06-05 | Nielsen Kirk G. | Director | A-Award | A | Stock Option (right to buy) | 12,012 | 12.33 | 148.1K | 12,012 | — | ↗ |
| 2023-06-05 | Jain Mudit K. | Director | A-Award | A | Stock Option (right to buy) | 12,012 | 12.33 | 148.1K | 12,012 | — | ↗ |
| 2023-06-05 | Hykes Kevin | Director | A-Award | A | Stock Option (right to buy) | 12,012 | 12.33 | 148.1K | 12,012 | — | ↗ |
| 2023-06-05 | Behbahani Ali | Director | A-Award | D | Stock Option (right to buy) | 12,012 | 12.33 | 148.1K | 12,012 | — | ↗ |
| 2023-05-16 | Palmer Craig E. | Officer | M-Exempt | A | Common Stock | 295 | 0.24 | 69.92 | 295 | — | ↗ |
| 2023-01-18 | Yared Nadim | Director / Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 0.00 | — | 200,000 | — | ↗ |
| 2023-01-18 | VERRASTRO PAUL | Director / Officer | A-Award | A | Stock Option (right to buy) | 45,000 | 0.00 | — | 45,000 | — | ↗ |
| 2023-01-18 | Palmer Craig E. | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2023-01-18 | OASHEIM JARED | Director / Officer | A-Award | A | Stock Option (right to buy) | 70,000 | 0.00 | — | 70,000 | — | ↗ |
| 2023-01-18 | Galle Liz | Director | A-Award | A | Stock Option (right to buy) | 26,000 | 0.00 | — | 26,000 | — | ↗ |
| 2023-01-11 | Yared Nadim | Director / Officer | G-Gift | D | Common Stock | 7,080 | 0.00 | — | 20,255 | — | ↗ |
| 2022-12-21 | Hykes Kevin | Director | A-Award | A | Stock Option (right to buy) | 5,246 | 0.00 | — | 5,246 | — | ↗ |
| 2022-11-30 | VERRASTRO PAUL | Director / Officer | G-Gift | D | Common Stock | 4,400 | 0.00 | — | 0 | — | ↗ |
| 2022-11-28 | VERRASTRO PAUL | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 9,000 | 0.00 | — | 84,556 | — | ↗ |
| 2022-08-02 | Yared Nadim | Director / Officer | A-Award | A | Stock Option (right to buy) | 60,000 | 0.00 | — | 60,000 | — | ↗ |
| 2022-08-02 | VERRASTRO PAUL | Director / Officer | A-Award | A | Stock Option (right to buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-08-02 | Palmer Craig E. | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2022-08-02 | OASHEIM JARED | Director / Officer | A-Award | A | Stock Option (right to buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-08-02 | Galle Liz | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 0.00 | — | 8,000 | — | ↗ |
| 2022-08-02 | BRUHN-DING DEAN | Director | A-Award | A | Stock Option (right to buy) | 6,000 | 0.00 | — | 6,000 | — | ↗ |
| 2022-06-07 | SLATTERY JOSEPH P | Director | A-Award | A | Stock Option (right to buy) | 26,985 | 0.00 | — | 26,985 | — | ↗ |
| 2022-06-07 | SHADAN MARTHA | Director | A-Award | A | Stock Option (right to buy) | 26,985 | 0.00 | — | 26,985 | — | ↗ |
| 2022-06-07 | Nielsen Kirk G. | Director | A-Award | A | Stock Option (right to buy) | 26,985 | 0.00 | — | 26,985 | — | ↗ |
| 2022-06-07 | NEHRA JOHN M | Director | A-Award | A | Stock Option (right to buy) | 26,985 | 6.76 | 182.4K | 26,985 | — | ↗ |
| 2022-06-07 | Jain Mudit K. | Director | A-Award | A | Stock Option (right to buy) | 26,985 | 0.00 | — | 26,985 | — | ↗ |
| 2022-06-07 | Behbahani Ali | Director | A-Award | A | Stock Option (right to buy) | 26,985 | 0.00 | — | 26,985 | — | ↗ |
| 2022-06-02 | OASHEIM JARED | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 3,160 | 0.00 | — | 0 | — | ↗ |
| 2022-05-24 | Nielsen Kirk G. | Director | P-Purchase | A | Common Stock | 8,070 | 5.05 | 40.8K | 1,711,355 | — | ↗ |
| 2022-05-23 | Nielsen Kirk G. | Director | P-Purchase | A | Common Stock | 4,432 | 5.04 | 22.3K | 1,703,285 | — | ↗ |
| 2022-05-20 | Nielsen Kirk G. | Director | P-Purchase | A | Common Stock | 13,387 | 5.04 | 67.4K | 1,698,853 | — | ↗ |
| 2022-05-19 | Nielsen Kirk G. | Director | P-Purchase | A | Common Stock | 10,976 | 5.04 | 55.3K | 1,685,466 | — | ↗ |
| 2022-05-04 | Nielsen Kirk G. | Director | P-Purchase | A | Common Stock | 25,503 | 5.99 | 152.8K | 1,670,498 | — | ↗ |
| 2022-05-03 | Nielsen Kirk G. | Director | P-Purchase | A | Common Stock | 3,992 | 6.00 | 23.9K | 1,674,490 | — | ↗ |
| 2022-04-28 | Nielsen Kirk G. | Director | P-Purchase | A | Common Stock | 41,988 | 5.97 | 250.7K | 1,612,186 | — | ↗ |
| 2022-04-25 | Yared Nadim | Director / Officer | M-Exempt | A | Common Stock | 6,059 | 0.24 | 1.4K | 27,335 | — | ↗ |
| 2022-04-22 | BRINTNALL JOHN | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 1,264 | 0.00 | — | 0 | — | ↗ |
| 2022-02-28 | Jain Mudit K. | Director | P-Purchase | A | Common Stock | 600 | 9.03 | 5.4K | 3,400 | — | ↗ |
| 2022-02-24 | Nielsen Kirk G. | Director | P-Purchase | A | Common Stock | 3,400 | 8.24 | 28.0K | 1,570,098 | — | ↗ |
| 2022-02-23 | Nielsen Kirk G. | Director | P-Purchase | A | Common Stock | 38,200 | 8.04 | 307.1K | 1,566,698 | — | ↗ |
| 2022-02-22 | Nielsen Kirk G. | Director | P-Purchase | A | Common Stock | 40,008 | 7.94 | 317.7K | 1,528,498 | — | ↗ |
| 2022-02-18 | Nielsen Kirk G. | Director | P-Purchase | A | Common Stock | 26,659 | 7.92 | 211.2K | 1,488,490 | — | ↗ |
| 2022-02-08 | BRUHN-DING DEAN | Officer | M-Exempt | A | Common Stock | 2,862 | 0.24 | 678.29 | 35,673 | — | ↗ |
| 2022-02-03 | Yared Nadim | Director / Officer | M-Exempt | A | Common Stock | 1,266 | 0.24 | 300.04 | 21,276 | — | ↗ |
| 2022-01-21 | Palmer Craig E. | Officer | — | D | Stock Option | 7,527 | 4.35 | 32.7K | 0 | — | ↗ |
| 2022-01-19 | Yared Nadim | Director / Officer | G-Gift | D | Common Stock | 10,500 | 0.00 | — | 2,586 | — | ↗ |
| 2022-01-18 | Yared Nadim | Director / Officer | A-Award | A | Stock Option (right to buy) | 186,400 | 9.08 | 1.69M | 186,400 | — | ↗ |
| 2022-01-18 | VERRASTRO PAUL | Officer | A-Award | A | Stock Option (right to buy) | 41,200 | 9.08 | 374.1K | 41,200 | — | ↗ |
| 2022-01-18 | OASHEIM JARED | Officer | A-Award | A | Stock Option (right to buy) | 56,200 | 9.08 | 510.3K | 56,200 | — | ↗ |
| 2022-01-18 | Galle Liz | Officer | A-Award | A | Stock Option (right to buy) | 25,900 | 9.08 | 235.2K | 25,900 | — | ↗ |
| 2022-01-18 | BRUHN-DING DEAN | Officer | A-Award | A | Stock Option (right to buy) | 23,600 | 9.08 | 214.3K | 23,600 | — | ↗ |
| 2022-01-13 | SLATTERY JOSEPH P | Director | M-Exempt | D | Stock Option (right to buy) | 758 | 0.24 | 179.65 | 0 | — | ↗ |
| 2021-12-30 | BRINTNALL JOHN | Officer | M-Exempt | A | Common Stock | 2,550 | 0.24 | 604.35 | 10,450 | — | ↗ |
| 2021-12-28 | Yared Nadim | Director / Officer | M-Exempt | A | Common Stock | 2,080 | 0.24 | 492.96 | 13,086 | — | ↗ |
| 2021-11-30 | SLATTERY JOSEPH P | Director | M-Exempt | D | Stock Option (right to buy) | 3,000 | 0.24 | 711.00 | 2,373 | — | ↗ |
| 2021-11-24 | BRUHN-DING DEAN | Officer | M-Exempt | A | Common Stock | 14,000 | 0.24 | 3.4K | 19,648 | — | ↗ |
| 2021-11-22 | Yared Nadim | Director / Officer | M-Exempt | A | Common Stock | 11,006 | 0.24 | 2.6K | 11,006 | — | ↗ |
| 2021-11-19 | Jain Mudit K. | Director | P-Purchase | A | Common Stock | 300 | 13.69 | 4.1K | 2,800 | — | ↗ |
| 2021-11-18 | Jain Mudit K. | Director | P-Purchase | A | Common Stock | 875 | 14.63 | 12.8K | 2,500 | — | ↗ |
| 2021-08-12 | Jain Mudit K. | Director | P-Purchase | A | Common Stock | 625 | 19.72 | 12.3K | 1,625 | — | ↗ |
| 2021-07-12 | SHADAN MARTHA | Director | A-Award | A | Stock Option (right to buy) | 9,988 | 20.10 | 200.8K | 9,988 | — | ↗ |
| 2021-07-02 | SLATTERY JOSEPH P | Director | A-Award | A | Common Stock | 5,555 | 18.00 | 100.0K | 5,555 | — | ↗ |
| 2021-07-02 | Pardo Geoffrey B | Director | C-Conversion | D | Series G Preferred Stock | 24,583,397 | 0.00 | — | 0 | — | ↗ |
| 2021-07-02 | Nielsen Kirk G. | Director | C-Conversion | D | Series G Preferred Stock | 23,125,000 | 0.00 | — | 0 | — | ↗ |
| 2021-07-02 | NEW ENTERPRISE ASSOCIATES 10 L P | 10% Owner | C-Conversion | D | Series G Preferred Stock | 18,934,168 | 0.00 | — | 0 | — | ↗ |
| 2021-07-02 | NEHRA JOHN M | Director | P-Purchase | A | Common Stock | 27,777 | 18.00 | 500.0K | 28,266 | — | ↗ |
| 2021-07-02 | NEA PARTNERS 10 L P | 10% Owner | P-Purchase | A | Common Stock | 24,750 | 18.00 | 445.5K | 173,388 | — | ↗ |
| 2021-07-02 | Jain Mudit K. | Director | P-Purchase | A | Common Stock | 222,222 | 18.00 | 4.00M | 933,383 | — | ↗ |
| 2021-07-02 | JOHNSON & JOHNSON | 10% Owner | C-Conversion | D | Series E-2 Preferred Stock | 6,451,188 | 0.00 | — | 0 | — | ↗ |
| 2021-07-02 | GLAXOSMITHKLINE PLC | 10% Owner | C-Conversion | D | Series B-2 Preferred Stock | 59,527 | 0.00 | — | 0 | — | ↗ |
| 2021-07-02 | BRINTNALL JOHN | Officer | C-Conversion | A | Common Stock | 5,658 | 0.00 | — | 7,900 | — | ↗ |
| 2021-07-01 | NEHRA JOHN M | Director | P-Purchase | A | Common Stock | 50 | 25.80 | 1.3K | 100 | — | ↗ |
| 2021-07-01 | Jain Mudit K. | Director | P-Purchase | A | Common Stock | 1,000 | 25.10 | 25.1K | 1,000 | — | ↗ |
| 2021-06-30 | NEHRA JOHN M | Director | P-Purchase | A | Common Stock | 50 | 27.43 | 1.4K | 50 | — | ↗ |
| 2021-06-29 | Yared Nadim | Director / Officer | — | I | Common Stock | 0 | 0.00 | — | 7,585 | — | ↗ |
| 2021-06-29 | VERRASTRO PAUL | Officer | — | D | Stock Option | 30,342 | 7.12 | 216.0K | 0 | — | ↗ |
| 2021-06-29 | SLATTERY JOSEPH P | Director | — | D | Stock Option | 1,264 | 5.14 | 6.5K | 0 | — | ↗ |
| 2021-06-29 | Pardo Geoffrey B | Director | — | I | Stock Option | 758 | 3.96 | 3.0K | 0 | — | ↗ |
| 2021-06-29 | OASHEIM JARED | Officer | — | D | Stock Option | 3,160 | 0.24 | 748.92 | 0 | — | ↗ |
| 2021-06-29 | Nielsen Kirk G. | Director | — | I | Series G Preferred Stock | 1,461,831 | 0.00 | — | 0 | — | ↗ |
| 2021-06-29 | NEW ENTERPRISE ASSOCIATES 10 L P | 10% Owner | — | D | Series D-2 Preferred Stock | 80,178 | 0.00 | — | 0 | — | ↗ |
| 2021-06-29 | NEHRA JOHN M | Director | — | D | Stock Option | 5,373 | 0.24 | 1.3K | 0 | — | ↗ |
| 2021-06-29 | NEA PARTNERS 10 L P | 10% Owner | — | I | Series D-2 Preferred Stock | 10,371 | 0.00 | — | 0 | — | ↗ |
| 2021-06-29 | Jain Mudit K. | Director | — | I | Stock Option | 1,264 | 5.14 | 6.5K | 0 | — | ↗ |
| 2021-06-29 | JOHNSON & JOHNSON | 10% Owner | — | I | Stock Option (Right to Buy) | 758 | 3.96 | 3.0K | 0 | — | ↗ |
| 2021-06-29 | Galle Liz | Officer | — | D | Stock Option | 25,285 | 7.12 | 180.0K | 0 | — | ↗ |
| 2021-06-29 | GLAXOSMITHKLINE PLC | 10% Owner | — | I | Series F-2 Preferred Stock | 27,345 | 0.00 | — | 0 | — | ↗ |
| 2021-06-29 | Behbahani Ali | Director | A-Award | A | Stock Option (right to buy) | 10,382 | 18.00 | 186.9K | 10,382 | — | ↗ |
| 2021-06-29 | BRUHN-DING DEAN | Officer | — | D | Stock Option | 18,963 | 7.12 | 135.0K | 0 | — | ↗ |
| 2021-06-29 | BRINTNALL JOHN | Officer | — | D | Stock Option | 18,963 | 7.12 | 135.0K | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-248.9K
Shares Outstanding
26.31M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Philip Adamson Chief Medical Officer | 549.5K | — | 259.2K | 307.5K | 231.1K | 13.8K | 1.36M | 41.63% | ↗ |
| 2 | 2024 | Nadim Yared Former President and Chief Executive Officer | 70.2K | — | — | 8.80M | — | 212.1K | 9.08M | 96.89% | ↗ |
| 3 | 2024 | Kevin Hykes President and Chief Executive Officer | 569.9K | 165.3K | — | 7.82M | 184.7K | 13.8K | 8.76M | 89.34% | ↗ |
| 4 | 2024 | Jared Oasheim Chief Financial Officer | 414.0K | — | — | 1.05M | 89.5K | 13.8K | 1.57M | 67.03% | ↗ |
| 5 | 2024 | Robert John Chief Revenue Officer | 241.2K | — | — | 1.12M | 111.9K | 10.7K | 1.49M | 75.57% | ↗ |
| 6 | 2023 | Nadim Yared Former President and Chief Executive Officer | 577.3K | — | — | 2.12M | 448.3K | 851.00 | 3.14M | 67.34% | ↗ |
| 7 | 2023 | Nadim Yared Former President and Chief Executive Officer | 577.3K | — | — | 2.12M | 448.3K | 851.00 | 3.14M | 67.34% | ↗ |
| 8 | 2023 | Jared Oasheim Chief Financial Officer | 380.0K | — | — | 740.7K | 196.7K | — | 1.32M | 56.22% | ↗ |
| 9 | 2023 | Jared Oasheim Chief Financial Officer | 380.0K | — | — | 740.7K | 196.7K | — | 1.32M | 56.22% | ↗ |
| 10 | 2023 | Paul Verrastro Chief Marketing and Strategy Officer | 390.0K | — | — | 476.1K | 209.0K | — | 1.08M | 44.29% | ↗ |
| 11 | 2022 | Nadim Yared Former President and Chief Executive Officer | 530.4K | — | — | 1.22M | 233.2K | 654.00 | 1.98M | 61.43% | ↗ |
| 12 | 2022 | Nadim Yared President and Chief Executive Officer | 530.4K | — | — | 1.22M | 233.2K | 654.00 | 1.98M | 61.45% | ↗ |
| 13 | 2022 | Paul Verrastro Chief Marketing and Strategy Officer | 367.5K | 30.0K | — | 303.3K | 132.3K | — | 833.1K | 36.40% | ↗ |
| 14 | 2022 | Jared Oasheim Chief Financial Officer | 345.0K | — | — | 376.7K | 101.1K | — | 822.8K | 45.78% | ↗ |
| 15 | 2021 | Nadim Yared President and Chief Executive Officer | 481.0K | — | — | 880.7K | 300.9K | 7.2K | 1.67M | 52.74% | ↗ |
| 16 | 2021 | Nadim Yared President and Chief Executive Officer | 481.0K | — | — | 880.7K | 300.9K | 7.2K | 1.67M | 52.74% | ↗ |
| 17 | 2021 | Paul Verrastro Chief Marketing Officer | 348.9K | 325.0K | — | 421.7K | — | — | 1.10M | 38.49% | ↗ |
| 18 | 2021 | Paul Verrastro Chief Marketing and Strategy Officer | 348.9K | 325.0K | — | 421.7K | — | — | 1.10M | 38.49% | ↗ |
| 19 | 2021 | Jared Oasheim Chief Financial Officer | 280.1K | — | — | 363.6K | 116.6K | — | 760.3K | 47.82% | ↗ |
| 20 | 2021 | Jared Oasheim Chief Financial Officer | 280.1K | — | — | 363.6K | 116.6K | — | 760.3K | 47.82% | ↗ |
| 21 | 2020 | Nadim Yared President and Chief Executive Officer | 452.0K | — | — | 344.7K | 196.6K | 13.3K | 1.01M | 34.25% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kevin Hykes | President, Chief Executive Officer & Director | 3M | male |
| Philip Adamson | Chief Medical Officer | 1M | — |
| Robert Allen John | Chief Revenue Officer | 1M | male |
| Paul Verrastro | Chief Marketing & Strategy Officer | 599.0K | male |
| Jared Oasheim | Chief Financial Officer | 517.3K | male |
| Jonelle R. Burnham | Vice President & General Counsel | — | female |
| Brent Binkowski | Chief Operating Officer | — | male |
| Gregory Morrison | Chief Human Resources Officer | — | male |
| Bonnie Handke | Senior Vice President of Patient Access, Reimbursement, & Healthcare Economics | — | female |
ESG Rating
ESG Score History MEDICAL - DEVICES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CVRX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
